Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

By M. Omata, A. Cheng, N. Kokudo, M. Kudo, Jeong Min Lee, J. Jia, R. Tateishi, K. Han, Y. K. Chawla, S. Shiina and 11 more. Hepatology International, 2017

2,032 citations recorded by the source corpus.

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/e24257ec886e8d22661c6527c3f29a151214c880

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Llovet
2. Amit G. Singal
3. F. Kanwal

In Hepatology

1. Amit G. Singal
2. F. Kanwal
3. J. Llovet
4. Jordi Bruix1 , 2
5. Riccardo Lencioni

Citations in the corpus

• Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023, methodology): “criteria 91,92,190 to 40–50% and 9–10%, respectively, for those selected using less-stringent criteria 107,192 (Table 3).”